文献速递胸部肿瘤

RET重排非小细胞肺癌的临床与转化意义

Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2017-11-08

该综述总结NSCLC中RET重排至少12种融合变异,KIF5B-RET最常见;IHC不能充分检测RET融合,需FISH与RT-PCR互补;多靶点抑制剂反应率16%-47%、PFS 2-7个月,毒性高,需更选择性RET抑制剂。

要点

  • RET融合需FISH和RT-PCR互补检测,IHC不适用。
  • RET重排多见于腺癌、不吸烟、年轻及晚期患者。
  • 多靶点抑制剂疗效有限且毒性高,需开发选择性RET抑制剂。

核心结论

  • RET重排NSCLC多靶点抑制剂疗效有限且毒性高,亟需开发更选择性且强效的RET抑制剂并明确耐药机制。

研究设计与样本

  • 本文为综述,汇总RET重排NSCLC的融合变异、检测方法、临床特征及多靶点抑制剂研究数据。

主要发现

  • 已发现至少12种RET融合变异,KIF5B-RET最常见且特征最明确。
  • 大型回顾性研究中RET重排与腺癌、不吸烟、年轻、晚期、潜在更高化疗敏感性及共存基因组改变相关。
  • 多靶点抑制剂客观缓解率16%-47%,无进展生存期2-7个月,严重毒性导致频繁减量和停药。
  • RET融合变异对anti-RET疗效的影响尚无定论,数据多来自小型亚组分析且不一致。

关键数值与推荐

  • RET融合不能通过IHC充分检测,FISH和RT-PCR为完全互补的诊断工具。
  • 多靶点抑制剂反应率16%-47%,无进展生存期2-7个月。

临床怎么用

  • 对NSCLC患者应联合FISH和RT-PCR检测RET融合,不依赖IHC。
  • 使用多靶点anti-RET药物时需密切监测毒性并管理剂量调整。
  • 优先考虑临床试验中更选择性的RET抑制剂。

局限性

  • RET融合变异对疗效影响的数据多来自小型亚组分析且不一致,无法得出确定性结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Since the discovery in 2012 of rearranged during transfection proto-oncogene gene (RET) rearrangements in NSCLC, at least 12 different fusion variants have been identified, with kinesin family member 5B gene (KIF5B)-RET being the most frequent and the best characterized. Unlike ALK receptor tyrosine kinase gene (ALK) and ROS1 rearrangements, RET fusion genes cannot be adequately detected by immunohistochemistry (IHC), although fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction are fully complementary diagnostic tools. In large retrospective studies, RET rearrangements correlate with adenocarcinoma histologic subtype, never-smoking status, younger age, more advanced disease stage, potentially higher chemosensitivity (in particular, to pemetrexed-based regimens), and coexistence of other genomic alterations. To date, several preclinical models, clinical trials, and retrospective studies have investigated multitarget inhibitors with anti-rearranged during transfection proto-oncogene (RET) activity in patients with RET-rearranged lung cancer. In the clinical setting, the benefit in terms of response (16%-47%) and progression-free survival (2-7 months) is clearly not comparable to that seen with other targeted agents in oncogene-addicted NSCLC. Furthermore, multikinase agents showed high rates of severe toxicities, leading to frequent dose reduction and drug discontinuation. To date, no definitive conclusions about a potentially different impact of anti-RET therapies according to RET fusion variants have been drawn on account of discordant data coming mostly from small subgroup analyses. Importantly, the absence of a striking clinical benefit in RET oncogene-addicted NSCLC underscores the clear need for development of more selective and potent RET inhibitors and for better characterization of concomitant genomic alterations and mechanisms of resistance to RET inhibition in patients with lung cancer.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Ferrara R, Auger N, Auclin E, et al. Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer. J Thorac Oncol. 2017. PMID: 29128428. doi:10.1016/j.jtho.2017.10.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。